- NEWS
Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left guessing how to achieve similar results.
Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, has announced an even more powerful artificial-intelligence model — and the company is keeping the innovation to itself.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 651, 18 (2026)
doi: https://doi.org/10.1038/d41586-026-00365-7
References
Jumper, J. et al. Nature 596, 583–589 (2021).
Abramson, J. et al. Nature 630, 493–500 (2024).
Passaro, S. et al. Preprint at bioRxiv https://doi.org/10.1101/2025.06.14.659707 (2025).
Related Articles
-
AlphaFold is running out of data — so drug firms are building their own version
-
AlphaFold is five years old — these charts show how it revolutionized science
-
‘The entire protein universe’: AI predicts shape of nearly every known protein
-
Chemistry Nobel goes to developers of AlphaFold AI that predicts protein structures
-
Atomic-level structures show how accuracy is maintained in protein synthesis
-
‘It will change everything’: DeepMind’s AI makes gigantic leap in solving protein structures
-
Link - This AI has chemical expertise — and helps synthesize 35 new compounds
